top-drug-discovery-and-development-solution-companies - drug-discovery-and-development Companies
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

BennuBio: A Potential Breakthrough in Cellular Analysis
line

Top 10 Drug Discovery and Development Solution Companies - 2020

line

Over the past 100 years, drugs discovered by the pharmaceutical industry have drastically changed the practice of medicine and impacted several aspects of society. Drug discovery was always based on ethnobotanical knowledge with a target and mechanism-agnostic approach. However, today, with the advent of modern molecular biology methods and a better understanding of the human genome, drug discovery has changed into a hypothesis-driven target-based approach.

Evidently, this has made laboratories highly-computerized and automated, where pharma companies are actively using AI solutions to kick-start the entire R&D process. AI can reduce timelines of drug discovery and improve the agility of the research process, increase the accuracy of predictions on the efficacy and safety of drugs, and improve the opportunity to diversify drug pipelines.

In the past few years, a majority of pharma companies have started adopting various strategies to actively integrate AI into their drug discovery process by hiring AI experts and data analysts. A part of their strategy also includes investing in startups and collaborating with tech giants, and research centers. While it is too early to conclude which strategy will be more successful, organizations are adding an addendum to this strategy by adopting more than one AI solution at different stages of the drug discovery process and collaborating with several companies at a time. To stay competitive in the increasingly sophisticated technologies and an unstable economic environment, biopharma companies are also increasingly outsourcing research activities to contract research organizations (CROs). Several pharma companies are also implementing machine learning-based deep learning technology to transform the small molecule research field and identify new biologics such as therapeutic antibodies against cancer, fibrosis, and other diseases—this approach has reduced the time-to-market of the antibody therapeutics by 3-18 months.

At this juncture, many cutting-edge drug development solution providers and consulting companies are entering the domain with advanced and integrated offerings. To help the pharmaceutical sector strengthen its operational capabilities and simultaneously enable growth in the industry, Pharma Tech Outlook has compiled this edition. The list comprises prominent organizations in the industry that address issues pertinent to drug development by implementing current trends. Besides, the magazine also includes insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for the aspiring CXOs. We present to you Pharma Tech Outlook’s, “Top 10 Drug Discovery and Development Solution Providers – 2020.”

    Top Drug Discovery and Development Solution Companies

  • An emerging technology company that offers the Velocyt, a first-of-its-kind parallel flow cytometer that accommodates large multicellular spheroids and single cell analyses at 10–100x sample volume and event rates. In the context of COVID-19, this can potentially allow the rapid analysis of microemboli in blood samples. Another important application for large particle analysis is the measurement of multicellular spheroids and organoids, which are aggregates of different cells mimicking a tissue. BennuBio recently secured a Round B funding of $5M to go with another $1M SBIR grant from the National Institute of General Medical Sciences to develop the HTSSP. While the one-laser Velocyt model V1 is currently for sale, the two-laser model will reach the market by Q2 of 2022, and a beta version of the HTSSP will be made available by late 2022

    www.bennubio.com

  • Biosensing Instrument (BI), a life sciences company, is turning the corner for the pharma and research organizations with its unique biotech instrumentation solutions aimed at helping researchers take the right step from the start. The company’s surface plasmon resonance microscopy system SPRm200 helps drug development teams in resolving inefficiencies in early stages of the drug discovery process by enabling real efficacy measurements directly in live cells in conditions close to a living body. The company’s tools for studying binding behavior provide real-time, label-free binding analysis of affinity and kinetics directly on live cells

    biosensingusa.com

  • Amberstone Biosciences

    Amberstone Biosciences

    Amberstone Biosciences discover transformative therapeutic antibodies through innovative technologies and creative partnerships to benefit patients with unmet medical needs. With a bold vision to pioneer a new wave of therapeutic breakthroughs, our team of dedicated and passionate scientists and entrepreneurs strive to discover transformative therapeutic antibodies through innovative technologies and creative partnerships to benefit patients with unmet medical needs

  • Antigen Discovery Inc.

    Antigen Discovery Inc.

    Antigen Discovery Inc. provides research services and products specializing in high throughput protein microarray technology that simplifies proteomic biomarker discovery and enables serological and immune profiling of whole proteomes.ADI’s powerful proteome microarray approach significantly decreases the time and cost required to perform proteome-wide antigen screening by eliminating time consuming steps in traditional cloning, protein expression and screening methodologies. ADI’s flexible and robust microarray platform facilitates the discovery of diagnostic biomarkers, vaccine candidates, as well as therapeutic antibody discovery and target validation

  • Bioelectronica

    Bioelectronica

    Bioelectronica is a research-stage biotechnology company building intelligent, digital tools for drug discovery, cell screening and cell sorting. After achieving entrepreneurial success in California's Silicon Valley and contributing to the next generation of DNA sequencing, Roger Chen founded Bioelectronica with co-founder Jonathan Hull. Biolectronica is building cutting-edge tools that use computer vision, biochemical reagents and consumer electronics to accelerate drug discovery. In January 2020, the Society for Laboratory Automation and Screening selected Bioelectronica’s Hypercell technology platform as the most innovative new product from around the globe that is “going above and beyond in their advancements of life sciences technologies."

  • Harbour BioMed

    Harbour BioMed

    Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.We are building a robust pipeline with our integrated Harbour antibody platform, that enable us to develop highly differentiated antibodies against various disease targets with great potency and safety profiles. Our proprietary Harbour Mice® generate fully human monoclonal antibodies in the classical two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon our HCAb antibodies, the HCAb-based immune cell engagers (HBICETM) are capable of delivering tumor killing effects unachievable by combination therapies. Integrated with our single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies

  • IHMA

    IHMA

    IHMA is a premier provider of antimicrobial drug development studies. With laboratories in both the US and Europe, we partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. We are a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. We utilize state of the art technology, leading to first-class testing and data as well as sound economic frameworks. Our services can be customized to best align with our clients’ unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways

  • Intelligencia.ai

    Intelligencia.ai

    Intelligencia.ai uses Artificial Intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We therefore aim to bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster.Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers brings together and interprets disparate data across the life sciences industry. Our platform offers a suite of functionalities that provide unprecedented data clarity and Machine-Learning fueled predictions to enable critical decision making

  • Natures Toolbox

    Natures Toolbox

    Nature’s Toolbox™ is a Santa Fe-based R&D, bioinformatics and biomanufacturing start-up that has developed a unique, recombinant in vitro transcription/translation system for research- to mid-scale, host-independent biological manufacturing. The NTx™ platform enables high-throughput screening and fast prototyping of novel biological materials with defined qualities. Besides cell-free manufacturing, the NTx science allows real-time metabolic profiling of bacteria, fungi and plants (DruID™) to discover, characterize and ultimately produce new chemical entities (NCEs) and biosimilars with increased reproducibility at a reduced footprint and cost while also accelerating development. The vision of Nature’s Toolbox is to provide materials for a diverse product portfolio, to deliver solutions for difficult-to-make biologics, and to generate drug leads for clinical development, which counter infectious diseases and other health conditions that present a challenge to public health

  • SYNENTEC

    SYNENTEC

    SYNENTEC is a provider of high resolution fluorescence and brightfield cell imaging systems & automation peripherals for cell line development, upstream applications, drug discovery, cancer research, immunology, stemcell research and cell based assays. SYNENTEC's objective is to offer superior devices for attractive and reasonable prices to offer the opportunity to everyone to equip labs with automated high throughput cell imaging. SYNENTEC's distribution network brings NYONE and CELLAVISTA to customers around the world